Please assess the completion status of the following clinical trial:

Trial Title: Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with idiopathic PD.~* Patients with a Modified Hoehn and Yahr stage \<3.~Exclusion Criteria:~* Patients with a clinically significant or unstable medical or surgical condition that would preclude his/her safe and complete study participation.~* Patients with a clinically significant or unstable vascular disease.~* Patients with a clinically significant psychiatric illness, including a major depression, which compromises their ability to provide consent or participate fully in the study.~* Patients with a Mini Mental State Examination (MMSE) score ≤24.~* Patients with a diagnosis of melanoma or a history of melanoma, or a suspicious lesion.~Other inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rasagiline (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).